Vaginal Drug Delivery Had A Funding Problem—Merck Changed That
forbes.com · 1,480 words · saved by 1 readers
A Goldman Sachs veteran says this platform would have funded faster as a rectal drug. Merck disagreed. Here's what took so long.
Leadership ForbesWomen Vaginal Drug Delivery Had A Funding Problem—Merck Changed That By Geri Stengel , Contributor. Forbes contributors publish independent expert analyses and insights. Geri Stengel writes about the success factors of women entrepreneurs. Follow Author Apr 20, 2026, 07:00am EDT --:-- / --:-- This voice experience is generated by AI. Learn more . This voice experience is generated by AI. Learn more . Callavid, Calla Lily Clinical Care's tampon-shaped vaginal drug delivery device, is designed to hold medication in place during absorption, eliminating the leakage that plagues cu
related reading
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Varda: The Space Drug Factorynotboring.co
- Check out 5 pitch decks from successful female foundersbusinessinsider.com
- I wasted $40k on a fantastic startup idea - by Tom - TJCXblog.tjcx.me
- The Best Venture Firm You’ve Never Heard Ofgeneralist.com
- Medicine's Endgamenotboring.co
- Curious cases of financial engineering in biotechowlposting.com
- Scaling innovative solutions in women's health with software | Insight Partnersinsightpartners.com
- Drug Discovery for Menopause with Gero and AthenaBIOathenadao.substack.com
- Early-Stage Biotech Value Creation: The Roles of Equity and Partnershipsleadershipandbiotechnology.blogspot.com
- NewLimit raises $435M led by Founders Fund to bring longevity medicines to human trialsblog.newlimit.com
- Geri Stengel - Breaking Barriersforbes.com